Eli Lilly and Company: Colonic Neoplasms trials
The registry lists 11 Colonic Neoplasms studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 6Phase 2 6No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
- A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT02784795Phase 1Results posted
- A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)CompletedNCT01286818Phase 1Results posted
- A Study of Ramucirumab or Icrucumab in Colorectal CancerCompletedNCT01111604Phase 2Results posted
- A Study of IMC-1121B (Ramucirumab) in Colorectal CancerCompletedNCT00862784Phase 2Results posted
- A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and BevacizumabTerminatedNCT00845039Phase 2Results posted
- Enzastaurin for Patients With Metastatic Colorectal CancerCompletedNCT00192114Phase 2Results posted
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT04521686Phase 1
- Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationApproved for marketingNCT03906331